NASDAQ:CTSO
Cytosorbents Corporation Stock News
$0.93
+0.0500 (+5.68%)
At Close: May 06, 2024
CytoSorbents Reports Second Quarter 2021 Financial and Operational Results
04:15pm, Tuesday, 03'rd Aug 2021
MONMOUTH JUNCTION, N.J., Aug. 3, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using
MONMOUTH JUNCTION, N.J., July 30, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using bl
CytoSorbents to Report Second Quarter 2021 Operating and Financial Results
07:08am, Monday, 19'th Jul 2021
MONMOUTH JUNCTION, N.J., July 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery
Here's Why Cytosorbents Is Up 17% Today
04:37pm, Tuesday, 06'th Jul 2021
The biotech company took another step toward introducing a new way of performing bypass surgeries.
CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
08:12am, Tuesday, 06'th Jul 2021
CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intrao
MONMOUTH JUNCTION, N.J., July 6, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the full approval of its Investigational Device Exemption (IDE) application to conduct the pivot
CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications
07:08am, Tuesday, 01'st Jun 2021
MONMOUTH JUNCTION, N.J., June 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care therapy leader commercializing its CytoSorb® blood purification technology to treat
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference
07:00am, Thursday, 27'th May 2021
MONMOUTH JUNCTION, N.J., May 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly co
CytoSorb® Registered and Commercially Available in Singapore
07:08am, Tuesday, 25'th May 2021
MONMOUTH JUNCTION, N.J., May 25, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly co
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit
07:00am, Wednesday, 19'th May 2021
MONMOUTH JUNCTION, N.J., May 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® blood purification technology to treat deadly
CytoSorbents, Progenity Receive Funding For Product Development
03:30pm, Tuesday, 11'th May 2021
The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR
MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to trea
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q1 2021 Results - Earnings Call Transcript
11:18pm, Tuesday, 04'th May 2021
CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q1 2021 Results - Earnings Call Transcript
CytoSorbents to Report Q1 2021 Operating and Financial Results
01:55pm, Tuesday, 27'th Apr 2021
MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to
U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery
07:08am, Monday, 19'th Apr 2021
MONMOUTH JUNCTION, N.J., April 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U.
